Hydroxycarbamid Hikma

Hydroxycarbamide, the active ingredient in Hydroxycarbamid Hikma, is an antimetabolite presented as an oral formulation for oral use. It is employed in the management of several hematologic malignancies and blood disorders, acting on rapidly dividing cells to limit disease progression.

GNH USA supplies Hydroxycarbamid Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Hydroxycarbamide is used across a spectrum of hematologic cancers and blood disorders where abnormal cell proliferation is a key feature.

- Chronic myelogenous leukemia: reduces leukemic cell growth and improves survival. - Sickle cell disease: decreases frequency of painful crises by raising fetal hemoglobin levels. - Essential thrombocythemia: lowers platelet counts and mitigates thrombotic risk. - Polycythemia vera: controls red‑cell mass and reduces thrombosis. - Melanoma: used as an adjunct in selected advanced cases to inhibit tumor replication.

Hydroxycarbamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting - Abdominal pain or dyspepsia - Fatigue or weakness - Alopecia (hair loss) - Myelosuppression (low blood counts) - Diarrhea

Serious or Rare Side Effects: - Severe neutropenia or infection risk - Thrombocytopenia leading to bleeding - Aplastic anemia - Skin ulceration or necrosis - Hypersensitivity reactions (rash, fever, anaphylaxis) - Secondary malignancies (e.g., acute leukemia).

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood counts: perform regular complete blood counts to detect myelosuppression. - Assess renal function: adjust dosing in patients with impaired kidney function. - Avoid use in pregnancy: drug is classified as Category D due to fetal risk. - Use caution in elderly: increased susceptibility to toxicity. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Hydroxycarbamide can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Allopurinol: may increase bone‑marrow suppression. - Azathioprine: additive myelosuppressive effect. - Methotrexate: enhanced toxicity, especially hematologic.

Moderate Interactions (Monitor Closely): - NSAIDs: potential increase in renal toxicity. - Penicillins: may reduce hydroxycarbamide plasma levels. - Live vaccines: reduced immunogenic response, consider timing.